Lysine cream for diabetic foot ulcers

NewsBot · Oct 6, 2019

Members do not see these Ads. Sign Up.
A randomized, open-label, comparative study of lysine cream 15% with
standard therapy in the management of non-diabetic foot ulcer assessing
by Bates-Jensen wound assessment tool
Vani J et al
National Journal of Physiology, Pharmacy and Pharmacology

Background: Lysine is an essential amino acid that is not synthesized within the body. It is synthesized in higher plants through
a biochemical pathway. Many clinical trials have reported that amino acids play an important role in hastening the process of
healing by improving the local blood supply as growth factors. Aims and Objectives: This study aimed to establish wound
healing, efficacy, and tolerability of lysine cream (15%) in non-diabetic foot ulcer by Bates-Jensen wound assessment tool
(BWAT). Materials and Methods: A randomized, open-label, interventional, comparative, prospective parallel group study was
conducted on 20 subjects (participants) with non-diabetic ulcer. Participants were divided into two groups, namely, control and
test. The control group was treated with standard treatment and the test group was treated with standard therapy along with lysine
cream (15%) twice daily. Participants were screened by BWAT. Results: The 20 participants were allocated into two groups. The
control group was treated with standard treatment (n = 10). The test group received standard treatment followed by lysine 15%
cream. The mean ± standard deviation values indicate size and depth of the foot ulcer from the 1st week to 7th week. Both the groups
showed significant decrease in the size and depth of the ulcer over the period of 7 weeks. Assessment of the 1st week showed that
there is no significant decrease in the size of the ulcer. Overall mean difference of the control versus test groups indicated that the
lysine-treated group significantly decreased both the parameters than the standard therapy (control). Conclusion: Treatment with
lysine cream significantly improved wound healing in non-diabetic foot ulcer patients when compared to the standard therapy.
Click to expand...

NewsBot · Jan 19, 2022

Modified poly(L-lysine)-based structures as novel antimicrobials for diabetic foot infections, an in-vitro study
Alicia Grace et al
Source

Background: Wound infections occur as sequelae to skin trauma and cause significant hospitalizations, morbidity and mortality. Skin traumas arise more frequently in those with diabetes or cardiovascular disease and in these settings, may be chronic with poorer outcomes including lower limb amputation. Treatment of chronic wound infection is challenging due to antibiotic resistance and biofilm formation by bacteria including S. aureus and P. aeruginosa, which are among the most frequent causative pathogens. Managing these challenging infections requires new molecules and modalities. Methods: We evaluated antimicrobial and anti-biofilm activity of star-shaped poly(L-lysine) (PLL) polymers against S. aureus and P. aeruginosa strains and clinical isolates recovered from wounds including diabetic foot wounds (DFW) in a Dublin Hospital in 2019. A star-shaped PLL polypeptide series, specifically G2(8)PLL20, G3(16)PLL10, G4(32)PLL5 with variation in polypeptide chain length and arm-multiplicity, were compared to a linear peptide, PLL160 with equivalent number of lysine residues. Results: All PLLs, including the linear polypeptide, were bactericidal at 1μM against S. aureus 25923 and P. aeruginosa PAO1, with log reduction in colony forming units/ml between 2.7-3.6. PLL160 demonstrated similar killing potency against 20 S. aureus and five P. aeruginosa clinical isolates from DFW, mean log reductions: 3.04 ± 0.16 and 3.96 ± 0.82 respectively after 1 hour incubation. Potent anti-biofilm activity was demonstrated against S. aureus 25923 but for clinical isolates, low to moderate loss of biofilm viability was shown using PLL160 and G3(16)PLL10 at 50 μM (S. aureus) and 200 μM (P. aeruginosa) with high inter-isolate variability. In the star-shaped architecture, antimicrobial activity was retained with incorporation of 5-mer hydrophobic amino-acid modifications to the arms of the polypeptides (series G3(16)PLL20-coPLT5, G3(16)PLL20-coPLI5, G3(16)PLL20-coPLP5). Conclusion: These polypeptides offer structural flexibility for clinical applications and have potential for further development, particularly in the setting of diabetic foot and other chronic wound infections.
Keywords
Click to expand...

NewsBot · Jul 24, 2023

Efficacy of 15% lysine cream in treating diabetic foot ulcers: a randomized interventional study
Shashikumara Shashikumara et al
Int J Physiol Pathophysiol Pharmacol. 2023; 15(3): 88–97.

Background and Objective: Lysine is an essential amino acid involved in several biochemical pathways. It has been shown to enhance blood supply and target growth factors, leading to improved wound healing. The present study aimed to evaluate the efficacy and tolerability of a 15% lysine cream in treating diabetic foot ulcers, as measured by the Bates-Jensen Wound Assessment Tool (BWAT). Materials and Method: A randomized, open-label, interventional study was conducted on 40 volunteers with diabetic ulcers. The treatment group (n=20) received well-known treatment along with lysine cream (15%) twice daily, while the control group (n=20) received standard therapy alone. Wound healing was evaluated using the BWAT. The student t-test and one-way ANOVA were used to compare the clinical assessment parameters to the baseline. Results: Both groups showed a significant decrease in ulcer size, depth, edges, undermining, necrotic tissue type, necrotic tissue amount, exudate type, and exudate amount over six weeks, with no significant difference between the groups after the first week. The lysine-treated group showed a significant improvement in wound healing compared to the control group (P<0.05). Conclusion: The present study demonstrates that a 15% lysine cream can significantly improve wound healing in diabetic foot ulcer patients, as measured by the BWAT, compared to standard treatment alone. Further research is needed to confirm these findings and to explore the underlying mechanisms of lysine’s therapeutic effects.
Click to expand...

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer

Anti-fungal cream vs powder

Topical 1% propranolol cream for diabetic wounds

EMLA cream prior to verruca treatment

Interleukin 2 Topical Cream for Treatment of Diabetic Foot Ulcer:

Effect of Lavender Cream with or without Foot-bath on Anxiety, Stress and Depression

What is the best cream for dry skin?

Share This Page